Frölich S, Olliges A, Kern N, Schreiber Y, Narumiya S, Nüsing RM. Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition. Am J Physiol Renal Physiol 303: F209 -F219, 2012. First published May 9, 2012 doi:10.1152/ajprenal.00418.2011.-Pharmacological blockade of cyclooxygenase-2 (COX-2) causes impairment of kidney development. The present study was aimed at determining temporal expression pattern and activity of the PGE 2 synthetic pathway during postnatal nephrogenesis in mice and its association to the time window sensitive to COX-2 inhibition. During the first 10 days after birth, we observed transient induction of mRNA and protein for microsomal PGE synthase (mPGES)-1 between postnatal days 4 (P4) and P8, but not for mPGES-2 or cytosolic PGE synthase (cPGES). PGE2 synthetic activity using arachidonic acid and PGH2 as substrates and also urinary excretion of PGE2 were enhanced during this time frame. In parallel to the PGE2 system, COX-2 but not COX-1 expression was also transiently induced. Studying glomerulogenesis in EP receptor knockout mice revealed a reduction in glomerular size in EP1 Ϫ/Ϫ , EP2 Ϫ/Ϫ , and EP4 Ϫ/Ϫ mice, supporting the developmental role of PGE2. The most vulnerable time window to COX-2 inhibition by SC-236 was found closely related to the temporal expression of COX-2 and mPGES-1. The strongest effects of COX-2 inhibition were achieved following 8 days of drug administration. Similar developmental damage was caused by application of rofecoxib, but not by the COX-1-selective inhibitor SC-560. COX-2 inhibition starting after P10 has had no effect on the size of glomeruli or on the relative number of superficial glomeruli; however, growth of the renal cortex was significantly diminished, indicating the requirement of COX-2 activity after P10. Effects of COX-2 inhibition on renal cell differentiation and on renal fibrosis needed a prolonged time of exposition of at least 10 days. In conclusion, temporal expression of the PGE2 synthetic system coincides with the most vulnerable age interval for the induction of irreversible renal abnormalities. We assume that mPGES-1 is coregulated with COX-2 for PGE2 synthesis to orchestrate postnatal kidney development and growth.
IN HUMANS, IN UTERO EXPOSITION to nonsteroidal anti-inflammatory drugs is associated to impairment of renal functions and can cause renohistological defects such as small glomeruli, incomplete tubular differentiation, cortical growth, and finally renal failure in the neonate (20, 43) . The renal dysgenesis caused by NSAIDs points toward an important role of the cyclooxygenase (COX) pathway of arachidonic acid in renal development. Two forms of COX (COX-1 and COX-2) do exist, and both enzymes are expressed in the adult kidney. COX-2 expression has also been shown in human fetal kidneys at gestational age 15-24 wk, a time of active nephrogenesis, and in fetal kidneys from rats (21, 22, 45) . Studies on COX-2-deficient mice and experiments using the COX-2-selective inhibitor SC-236 have demonstrated that postnatal COX-2 activity is necessary for normal nephrogenesis in mice and rats (23) , whereas depletion of the COX-1 enzyme remains without detrimental influence on renal development (25) .
Nephrogenesis in the mouse kidney begins at embryonic day 11 and ends ϳ10 -14 days postpartum (P10-P14). During this period, new nephrons are continually being generated from the nephrogenic mesenchyme in response to signals emanating from the tips of the branching ureter (7) . The kidney continues to develop from the center toward the periphery, and the most mature nephrons are located in the inner cortex, the least mature in the outer cortex. In COX-2 Ϫ/Ϫ mice, kidneys appear neonatally normal, but later kidney development is impaired demonstrated by hypoplastic glomeruli, a thinned cortical area, and immature glomeruli. A reduced number of glomeruli, appearance of undifferentiated cells, and frequently medullary hyperplasia have also been observed in COX-2 Ϫ/Ϫ mice (8, 29) , in addition to periglomerular and diffuse interstitial fibrosis (32) . A recent study has shown that in mouse kidneys COX-2 protein is detectable at P4 and disappears thereafter (23) . However, it is unknown whether this time point represents the vulnerable time window for use of COX-2 inhibitors. Comparable to mice, rat kidney nephrogenesis also lasts until ϳP14 (28) . However, in contrast to mice, maximal expression of COX-2 protein has variably been observed on days P7 (38) , P14 (47) , or P15 (44) , which then declined until adulthood.
Although these observations gave clear evidence that COX-2 expression and activity are important prerequisites to ensure normal renal development in mice, the involved secondary prostanoid system and the exact time window for COX-2 necessity are not clarified in detail. COX is the ratelimiting step, but secondary PGH 2 -metabolizing enzymes are necessary to form specific prostanoids, and the kidney is able to produce all primary prostanoids, PGE 2 , PGI 2 , PGD 2 , PGF 2␣ , and thromboxane A 2 (for a review, see Ref. 37) , whereas an important physiological function has been attributed to PGE 2 . In support of a developmental role of PGE 2 in isolated glomeruli from 10-day-old rats, PGE 2 was found as a major cyclooxygenase product (3), and we observed PGE 2 as the major prostanoid in urine samples of P4 mouse pups (unpublished observations, Frölich S). Three different enzymes are reported to be able to catalyze the synthesis of PGE 2 from COX-derived PGH 2 : microsomal PGE synthase (mPGES)-1, mPGES-2, and cytosolic PGE synthase (cPGES), which are structurally and biologically distinct enzymes (for a review, see Refs. 12 and 24). mPGES-1 is markedly induced by proinflammatory stimuli and downregulated by anti-inflammatory glucocorticoids as in the case of COX-2. According to a recent report, it is functionally coupled with COX-2 in marked preference to COX-1 (31) . mPGES-2 is rather constitutively expressed in various cells and tissues and is thought to be functionally coupled to both COX-1 and COX-2 (30) . cPGES is constitutively expressed in a wide variety of cells, and evidence has been presented for functional association of cPGES and COX-1 to promote immediate PGE 2 production (39). However, the relevance of cPGES to the generation of PGE 2 in vivo has been questioned (26) . Distinct renal functions for the three PGE synthases have not yet been identified, but emerging evidence suggests a potential role for mPGES-1 in the proximal tubular response in aldosterone escape (17) and in the regulation of sodium homeostasis (9, 18) .
In the present paper, we questioned whether the PGE 2 system may be involved in COX-2-dependent regulation of renal development and whether vulnerability to COX-2 inhibition is associated with the PGE 2 biosynthetic system in a timely fashion. We hypothesize that, next to the COX-2 step in renal arachidonic acid cascade, the PGE synthase step is also subject to control during nephrogenesis. Therefore, we studied time-dependent postnatal renal expression of mPGES-1, mPGES-2, and cPGES, PGE 2 synthetic activity, and also urinary PGE 2 level in mice. With a view to associate alterations in the PGE 2 system to changes in the COX system, we also analyzed expression of COX-1 and COX-2 and the time frame of renal developmental sensitivity toward COX-2 inhibition. Addressing the issue will help in understanding the physiological role of the prostanoid system in renal development.
MATERIALS AND METHODS

Animals and treatment.
All animal care and experimental procedures were in accordance with institutional guidelines and approved by the Animal Welfare Committee of the State Agency (Darmstadt, Germany). Breeder pairs of C57/BL6J wild-type mice were obtained from Jackson Laboratories (Bar Harbor, ME). Breeder pairs of COX-2 Ϫ/Ϫ mice were kindly provided by Robert Langenbach (National Institute of Environmental Health Sciences, Research Triangle Park, NC) (29) . EP1-, EP2-, EP3-, and EP4-deficient mice were generated as previously described (15, 36, 42, 46) . All mice are backcrossed to C57BL6 more than 10 times. Mice of each gender were used in the study. Genotypes of the mice were determined by PCR analysis using specific oligonucleotides to the respective COX and EP locus and the Neo cassette. The animals were maintained in individually ventilated cages in a temperature-controlled (21°C) room with a 12:12-h lightdark cycle. Food and water were provided ad libitum.
The day of birth was defined postnatal day 0 (P0). Mice were treated with COX-2 inhibitor SC-236 (Enzo Life Sciences, Lörrach, Germany), rofecoxib (synthesized by Witega-Laboratory-Adlershofen, Berlin, Germany), and SC-560 (Calbiochem, Darmstadt, Germany), which were dissolved in DMSO and administrated at a dose of 10 mg·kg Ϫ1 ·day Ϫ1 (33) . Drugs were injected at the indicated time points, whereas from P1 to P6 injections were done subcutaneously (sc) between the shoulder blades of the pups and from P7 on intraperitoneally (ip). The volume injected was roughly adjusted to body weight, so that from P1 to P6, substances were dissolved in a volume of 5 l, from P7 to P14 in a volume of 7.5 l, and from P15 to P21 in a volume of 10 l. Control groups received DMSO alone. Random urine samples were collected daily at 10 a.m. and stored at Ϫ80°C until PGE 2 determination by EIA (AssayDesign, Ann Arbor, MI).
Tissue preparation and micrography. Following short-term anesthesia with isoflurane, mice were weighed and then euthanized by cardiac puncture. Kidneys were immediately removed, weighed, sagitally hemisected, and immersion-fixed overnight in 4% paraformaldehyde/PBS. Thereafter, kidney tissue was embedded in paraffin and sections were cut at a thickness of 4 m, dewaxed in xylene, and stained with hematoxylin and eosine. Renal histomorphometric analysis, with determination of mean diameter of glomeruli, subcapsular cortical thickness, and relative amount of superficial glomeruli, was done as described previously (33) . Briefly, three kidney sections at least 50 -60 m apart from six individual animals from each group were selected. Photomicrographs were obtained using Axioskop (Carl Zeiss MicroImaging, Göttingen, Germany) provided with an AxioCam digital camera and software, and a total of 300 glomeruli chosen at random from the superficial cortex, midcortex, and juxtamedullary region was digitized for each group. The cross-sectional diameter of glomeruli and the distances from the kidney edge to Bowman's capsule were measured perpendicularly to the renal capsule using National Institutes of Health ImageJ software. Glomeruli that appeared to be cut tangentially were excluded from the observation group. To count the relative number of superficial glomeruli, we set a distance limit of 74 m from the cortical edge, defined by the sum of the distance of glomeruli located nearest to the surface plus one mean diameter of glomeruli in control kidneys.
Immunoblotting. To obtain whole tissue extracts, kidneys were homogenized in 50 mM Tris·HCl, 1% Triton X-100, pH 7.4, supplemented with protease inhibitor cocktail (Merck, Darmstadt, Germany) using a potter-homogenizer and sonification. Following a 30-min centrifugation at 18.000 g at 4°C, the supernatant was removed. Protein concentrations were determined by the bicinchoninic acid method according to the manufacturer's protocol (Pierce, Rockford, IL) using BSA as a protein standard. Samples of 50 g protein were mixed with 4ϫ Laemmli sample buffer (0.1 mol/l Tris·HCl, 8% SDS, 40% glycerol, 0.1% bromophenol blue, 10% ␤-mercaptoethanol, pH 6.8) and heated for 10 min at 95°C. The samples were separated on 15% polyacrylamide minigels and transferred to nitrocellulose membranes (Protran, Whatmann, Dassel, Germany). The membranes were blocked with 5% nonfat dry milk in phosphate-buffered saline and incubated with the primary antibodies. The following antibodies were used: anti-COX-1 and anti-COX-2 (Cayman Chemical, Ann Arbor, MI) diluted 1:150, anti-mPGES-1 (AgriSera, Vännäs, Sweden) diluted 1:5,000, anti-mPGES-2 (Cayman Chemical) diluted 1:2,000, and anti-cPGES (Cayman Chemical) diluted 1: 50 in 5% nonfat dry milk in PBS containing 0.1% Tween 20 overnight at 4°C. After washing three times, membranes were incubated with secondary horseradish peroxidase-labeled antibody diluted 1:5,000 in 5% nonfat dry milk in PBS containing 0.1% Tween 20 for 1 h at room temperature. Immunodetected protein bands were visualized by the ECL detection system according to the instruction of the supplier (GE Healthcare, Freiburg, Germany).
Quantitative real-time PCR. Kidneys from mice were dissected and stored at Ϫ80°C until analysis. Total RNA was isolated using an RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The RNA concentration was quantified by A260 using a NanoDrop spectrophotometer (Peqlab Biotechnologie, Erlangen, Germany). RNA (0.5 g) was reverse transcribed using superscript II RNase and random hexamers (Invitrogen, Karlsruhe, Germany), and 1/40 volume of the resulting cDNA samples were used as templates for real-time PCR by using the SYBR Green supermix reaction procedure with the 7500 Fast System (Applied Biosystems, Darmstadt, Germany). All reactions were run in triplicate to minimize experimental error. The following primers pairs were used: for COX-1, GTG GCT ATT TCC TGC AGC TC and CAG TGC CTC AAC CCC ATA GT; for COX-2, GCA GTT GTT CCA GAC AAG CA and AAG GGG ATG CCA GTG ATA GA; for mPGES-1, ACA GGC CAG ATG AGG CTG CGG AA AND TCT CCA TGT CGT TGC GGT GGG CT; for mPGES-2, TTT GGG GCT GTG GAG GCT GCC AT AND ACC CAC GGC TGT CAC CCA CTT GT; for cPGES ATT TTG CTG CGT CAC CAG CCG CC AND TCG GCC TCG ATG CCC AGA ATG CAC; and for ␤-actin, TCC ATC ATG AAG TGT GAC GT AND GAG CAA TGA TCT TGA TCT TCA T. PCR was initiated at 95°C for 15 min followed by 40 cycles of 15 s at 95°C and 1 min at 60°C for annealing and extension. The expression of mRNA was assessed relative to that of ␤-actin, and the relative quantitative level of samples was determined by the standard 2 (Ϫ⌬⌬Ct) method and expressed as change (fold) relative to expression levels at P2.
Assay for PGE 2 synthetic activity. For determination of PGE2 synthesis, kidneys were weighed and rapidly homogenized in 2 vol (wt/vol) of cold tissue buffer (50 mM Tris, pH 7.4, 1 mM phenol, 1ϫ protease inhibitor cocktail set, Merck) with an ultraturax followed by ultrasonification (5-10 times for 2-4 s). Homogenates were centrifuged for 10 min at 3,000 g, and protein concentrations of the supernatants were determined. To determine COX-dependent PGE 2 synthesis, samples of 100 g protein were prewarmed at 37°C for 1 min, and reactions were started by the addition of arachidonic acid (final concentration 50 M). After 10 min of incubation, the reaction was stopped with 1% formic acid. To determine PGE synthasedependent PGE2 synthesis, samples of 1 mg protein were incubated at 4°C with PGH2 (final concentration 10 M), and the reaction was stopped after 2 min by the addition of FeCl2. PGE2 was extracted and determined by liquid chromatography tandem mass spectrometry as described (33) . In brief, for liquid-liquid extraction, samples were incubated twice with 600 l ethylacetate, and the organic phase was removed at 45°C under nitrogen. For reconstitution, 50 l of acetonitrile/water/formic acid (20:80:0.0025, vol/vol, pH 4.0) was used, and after centrifugation for 5 min at 18,000 g samples were used for injection. PGE2 was separated with a Synergi 150 ϫ 2-mm Hydro-RP column (Phenomenex, Aschaffenburg, Germany) and determined with an API 4000 triple-quadrupole mass spectrometer (AB Sciex, Darmstadt, Germany).
Histochemistry and immunohistochemistry. Kidney sections were fixed in 4% paraformaldehyde (PFA) for 16 -24 h and embedded in paraffin. Four-micrometer-thick paraffin sections were subjected to Sirius red staining (Science Services, Munich, Germany) to evaluate fibrosis by determination of the area of basement of Bowman's capsule as described (33) . For each group, 30 glomeruli were chosen randomly and digitally imaged. Glomeruli that appeared to be cut tangentially were excluded from the observation group. Quantitative analysis of the pictures was performed, without knowledge of the treatment, using Adobe Photoshop CS2 software and Quantity One (Bio-Rad, München, Germany), which allows counting of the pixels stained specifically. The results are given as stained area of basement of Bowman's capsule, normalized to glomerulus diameter.
Immunohistochemical studies for the detection of macrophages and the proliferating cell nuclear antigen (PCNA) were performed as recently described (33) . In brief, deparaffinized sections were incubated in a humidified atmosphere with the following primary antibodies: rat anti-mouse F4/80 (AbD Serotec, Oxford, UK), which reacts with interstitial macrophages, and rabbit anti-PCNA antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Before application of F4/80 antibody, sections were treated with a target-retrieval solution (Dako, Hamburg, Germany). For visualization of F4/80, the Dako ABC System was used, and for PCNA the Vectastain Elite System (Vector Laboratories, Burlingame, CA) according to the protocols of the suppliers. Sections were counterstained with hematoxylin. In negative controls, the primary antibody was omitted or replaced by nonimmune serum. Analysis was performed by an operator unaware of the origin of each kidney section. For PCNA and macrophage determination, marked cells per index field were counted. Under a light microscope at ϫ200 magnification, five to eight nonoverlapping fields (to obtain ϳ90% of the cortical kidney section) per kidney section were captured with a numeric camera connected to the microscope. Results are presented as positive cells/field.
Statistics. Data are presented as means Ϯ SE. Analysis were performed by ANOVA and a post hoc Bonferroni's multiple comparison test for all groups or Dunnett's multiple comparison test vs. the control group. Prism 5.0 software (GraphPad) was used for all calculations. A P value Ͻ0.05 was considered significant.
RESULTS
Postnatal renal expression of COX-1 and COX-2.
For COX-1, we observed no significant changes in renal expression, neither in mRNA nor in protein expression at the time points chosen (Fig. 1, A and B) . In contrast, postnatal expression of COX-2 was regulated time dependently (Fig. 1, C and  D) . Semiquantitative real-time PCR analysis revealed a significant rise in mRNA expression for COX-2 at P4 and P6, with a continuous decrease until P10, at which mRNA expression was similar to P21 (Fig. 1C) . COX-2 protein expression followed in a similar slightly time-shifted manner, with an expression peak reached on P6 (Fig. 1D ) lasting until P10. During this time course, COX-2 protein expression was increased about four-to fivefold compared with P2. On P21, COX-2 protein displayed a similar level of expression as on P2.
PGE 2 synthetic activity in the kidney. To investigate whether changes in renal COX-2 expression were paralleled by changes in renal PGE 2 synthetic activity, we determined enzymatic capacity of kidney tissue homogenates to synthesize PGE 2 from exogenously added arachidonic acid. Compared with P2, significantly elevated PGE 2 -synthesizing activities were observed from P4 until P10 (Fig. 2A) . The formation of PGE 2 could be blocked by the addition of 10 m indomethacin, indicating COX-dependent PGE 2 synthesis. Whereas addition of the COX-1 inhibitor SC-560 to kidney homogenates prepared from 8-day-old mice has had only minimal effect on enzymatic activity, the addition of SC-236 or rofecoxib significantly suppressed PGE 2 synthetic activity, indicating the importance of COX-2 to renal PGE 2 synthesis (Fig. 2A) . From P2 to P21, we collected spontaneous urine samples and determined excreted PGE 2 amounts. Compared with P2, urinary PGE 2 concentration was significantly elevated on P4, P6, P8, and P10, but not on P21 (Fig. 2B) . Compared with the vehicle-treated control group, treatment of wild-type mice with the COX-2-selective inhibitor SC-236 significantly reduced postnatal renal excretion of PGE 2 at any time point (Fig. 2B) . In accordance, treatment of wild-type mice with rofecoxib also decreased PGE 2 excretion (shown for P8, Fig. 2B ), whereas application of the COX-1 inhibitor SC-560 caused a minor, nonsignificant decrease in PGE 2 excretion. To clarify whether induction of COX-2 is sufficient for elevated PGE 2 synthesis or whether secondary PGE synthases are concomitantly induced, we also studied PGE 2 formation by kidney homogenates using PGH 2 as a substrate. Compared with P2, a significant rise in enzymatic activity was observed from P4 to P8 (Fig. 2C ), but not on P10. Elevated PGE 2 synthase activity was also detected in kidneys from 21-day-old mice.
Postnatal renal expression of mPGES-1, mPGES-2, and cPGES. To elucidate the role of specific PGE synthases for renal PGE 2 synthesis, we studied the postnatal expression of mPGES-1, mPGES-2, and cPGES. For mPGES-1, significantly elevated mRNA expression was detected on P6 and P21 (Fig. 3A) . In line with this observation, increased mPGES-1 protein expression was observed (Fig. 3B) , which reached significance on P4, P6, and P21 compared with P2. In striking contrast to mPGES-1, renal mRNA and protein expression of mPGES-2 and cPGES remained unchanged at the indicated postnatal time points (Fig. 3, C and D and E and F, respectively) .
Size of glomeruli in EP receptor-deficient mice. To further substantiate the developmental role of PGE 2 , we studied nephrogenesis in PGE 2 receptor-deficient mice. Determination of glomerular size on P21 revealed that minor but significantly impaired growth of glomeruli was detectable in EP1 Ϫ/Ϫ , EP2 Ϫ/Ϫ , and in EP4 Ϫ/Ϫ mice, whereas the growth of glomeruli in EP3 mice was not different from control (Fig. 4) .
Time-dependent effects of COX-2 inhibition on nephrogenesis. To determine whether the transient expression and activity of the PGE 2 system fall into the time frame of vulnerability toward COX-2 inhibition, we treated C57BL6/J wild-type mice with the selective COX-2 inhibitor SC-236 for different time courses. Administration of SC-236 from P1 to P2 already compromised the size of glomeruli, and we observed a significant reduction in mean diameter (control: 48.35 Ϯ 0.97 m; P1-P2: 41.53 Ϯ 0.93 m; P Ͻ 0.05) (Fig. 5, A and B) . Prolonged exposure to SC-236 further downsized glomeruli, with a maximal effect following administration until P10. Additional administration of the COX-2 inhibitor did not further diminish glomerular diameter, and the observed size reduction was quite similar to COX-2 Ϫ/Ϫ mice. Glomeruli from mice treated from P11 or P13-P20 were indistinguishable in mean diameter to control (Fig. 5, A and B) .
In control kidneys, a mean subcapsular cortical thickness of 56.84 Ϯ 1.24 m was observed. COX-2 inhibition P1 and P2 already caused a reduction by ϳ36% to 36.33 Ϯ 2.12 m (Fig.  5C ). The strongest cortical thinning was observed following administration of SC-236 from P1 to P8, which was significantly different to shorter times of exposure and comparable to the cortical defect in COX-2 Ϫ/Ϫ mice. However, from this time point on no further reduction in subcapsular cortical thickness could be induced. Of note, administration of SC-236 starting on P11 and on P13 also caused a significant attenuation of cortical growth, albeit to a lesser extent (Fig. 5C) .
Regarding the relative number of superficial glomeruli, we observed no significant difference from the control group following administration of SC-236 until P4 (Fig. 6A) . Longer exposure of kidneys to the COX-2 inhibitor caused a significant increase in superficial glomeruli, which reached a maximum at P8. The effect in the group at P1-P10 was slightly stronger, but the difference to the group at P1-P8 was not significant. However, the observed changes were less dramatic as in COX-2 Ϫ/Ϫ mice. Administration of SC-236 from P11 or P13-P20 was without an effect on the relative number of superficial glomeruli (Fig. 6A) . Histomorphological damage was not limited to SC-236-inhibited COX-2, as we observed similar changes in glomerular diameter and subcapsular thickness by application of rofecoxib (Fig. 6, B and C) . In accordance to previous reports (23, 33), we observed no effect of the COX-1 inhibitor SC-560 on glomerular or cortical growth (Fig.  6, B and C) .
Time-dependent effects of COX-2 inhibition on inflammatory responses, cell differentiation, and fibrosis.
In addition, we questioned whether different time courses of SC-236 adminis- tration would affect inflammatory responses, loss of cell differentiation, and fibrotic processes, reported to occur in COX-2 Ϫ/Ϫ mice (32) . We studied the number of interstitial macrophages by F4/80 staining used as an indicator of inflammatory response. Following administration of SC-236 for different time courses, only faint amounts in number of F4/80-positive cells were observed in all study groups (Fig. 7A) , indicating no significant effect of COX-2 inhibition on macrophage migration into renal tissue. Next, we evaluated cortical renal cell proliferation as a measure of undifferentiated cells by immune staining for PCNA. Only a very small number of PCNApositive cells were found in cortical sections of control kidneys on P21 (1.45 Ϯ 0.25 cells/index field), indicating that differentiation processes within the kidney are nearly finished at this time point (Fig. 7B) . For example, the number of PCNApositive cells on P2 reaches 21.25 Ϯ 1.76 cells/index field (Frölich S, data not shown). Following administration of SC-236 for different time frames, we detected a significant increase in PCNA-positive cell number compared with control only at P1-P10 and P1-P20 (Fig. 7B) . This finding indicates that a prolonged time of suppression of COX-2 activity is necessary to cause effects on renal cell differentiation. Periglomerular fibrosis was studied in Sirius red-stained kidney sections. Only continuous administration of COX-2 inhibitor SC-236 from P1 to P20 was able to raise the mean area of the basement membrane of Bowman's capsules significantly (Fig. 7C) .
DISCUSSION
The COX pathway of arachidonic acid is responsible for the synthesis of various prostanoids. In preliminary experiments, we identified PGE 2 as a major prostaglandin formed during the first postnatal days in mice. Therefore, we questioned, whether a time frame of susceptibility toward COX-2 inhibitors is associated with changes in PGE 2 -synthesizing capabilities. We observed that COX-2 expression is upregulated within the first postnatal days, with maximal expression of COX-2 between P4 and P10, shown by an increase in mRNA and protein expression as well as enzymatic COX activity demonstrated by enhanced arachidonic acid turnover to PGE 2 . COX-1 expression remained unchanged. Similarly, peak expression of COX-2 protein on P4 in mouse kidney has been reported (23) . Albeit COX-1 enzymatic activity was not studied, we assume that the increase in our COX activity assay and in renal PGE 2 excretion is mainly attributed to the increase in COX-2 expression. Although PGE 2 levels were determined in spot urine and may be influenced by hydration status or development of the concentrating ability of mice pups, a substantial decrease in PGE 2 excretion following SC-236 or rofecoxib administration is in line with our conclusion that in mouse kidney the COX-2 enzyme is responsible for altera- Fig. 3 . Time-dependent postnatal expression of microsomal PGE synthase (mPGES)-1, mPGES-2, and cytosolic PGE synthase (cPGES) mRNA and protein in mouse kidney. Kidneys were prepared at the indicated postnatal time points (P2, P4, P6, P8, P10 , and P21), and mRNA and whole kidney protein extracts were isolated and analyzed for mPGES-1 mRNA (A) and protein (B), mPGES-2 mRNA (C) and protein (D), and cPGES mRNA (E) and protein (F). mRNA analysis was performed by quantitative realtime PCR. Relative levels were determined by the standard 2 (Ϫ⌬⌬Ct) method, normalized to ␤-actin. Expression of PGE2 synthase proteins was done by immunoblotting using specific antibodies. Data are presented as change (fold) relative to expression levels at P2 (shown by open bar) and represent means Ϯ SE of 3 independent experiments. For mPGES-2 and cPGES, no significant differences between the time points were observed. *P Ͻ 0.05 vs. P2. tion in PGE 2 production within the first 10 days of life. In adult mice, it is suggested that mainly COX-1 contributes to renal PGE 2 formation under physiological conditions, whereas COX-2 activity is important under pathological conditions such as volume depletion, e.g., caused by longterm furosemide application (11) . The importance of PGE 2 for normal renal development is supported by our observation that distinct EP receptor-deficient mice also exhibit impaired nephrogenesis. The diminished diameter of the glomeruli in EP1 Ϫ/Ϫ , EP2 Ϫ/Ϫ , and EP4 Ϫ/Ϫ mice indicates a complex interaction of various EP receptors with glomerulogenesis. In support of our observation, a recent report has shown that in rat kidney EP1, EP2, and EP4 receptor mRNA and protein increased after birth and then decreased to adult levels, whereas EP3 receptor did not rise before 21 days of age (4) . Further studies will be necessary to elucidate the specific developmental roles of the distinct EP receptor types.
Our observation that biosynthetic formation of PGE 2 from PGH 2 is also transiently induced let us suggest that PGE 2 synthases secondary to COX-2 are regulated in a comparable way to COX-2. No data are available regarding early postnatal expression of PGE synthases. We observed a similar transient renal induction of mPGES-1 as for COX-2 in early postnatal life. In contrast, mPGES-2 and cPGES expression was unchanged, at least during the time points investigated. A simultaneous rise in expression of COX-2 and mPGES-1 fits quite well with the assumption that mPGES-1 is colocalized and coregulated with COX-2 to act in concert to mediate PGE 2 synthesis (31). An outstanding role of mPGES-1 in adult renal COX-2-dependent PGE 2 synthesis is also assumed. In mPGES-1-deficient mice, Francois et al. (9) observed an attenuation of COX-2-dependent, furosemide-induced urinary PGE 2 excretion. Furthermore, immunological studies have shown that in mice and rat kidney COX-2 and mPGES-1 are expressed colocalized in the macula densa and thick ascending limb of Henle, whereas mPGES-1 and COX-1 were expressed in the distal tubule and in the collecting duct (6) . Concerning transient temporal expression of COX-2 and mPGES-1 around P4-P8 and unaltered expression of COX-1, mPGES-2, and cPGES during this time frame, we hypothesize that concomitant induction of COX-2 and mPGES-1 by an as yet unidentified signal is necessary to deliver PGE 2 for normal postnatal development and maturation of the kidney. mPGES-2 is constitutively expressed in several tissues, and its level of expression is unaltered under inflammatory conditions and it utilizes PGH 2 deriving from COX-1 or COX-2 (30) . In contrast, cPGES has been proposed to functionally couple predomi- nantly with COX-1, thereby providing constitutive production of PGE 2 (39) . It remains speculative whether mPGES-2 and/or cPGES may be involved in PGE 2 synthesis required for kidney maturation after P10 as supposed from our data. Although our data clearly point toward mPGES-1 being linked to COX-2 for PGE 2 as necessary during the postnatal phase of nephrogenesis, mPGES-1 Ϫ/Ϫ mice do not exhibit obvious renal defects (40, 41) . Two possibilities may explain this contradictory observation. First, other sources, such as mPGES-2 or cPGES, may deliver necessary PGE 2 and thereby compensate for mPGES-1 deficiency. Second, shunt of arachidonic acid to other prostanoids or eicosanoids may replace for missing PGE 2 . This assumption is supported by our recent observation that spinal cord segments from mPGES-1 Ϫ/Ϫ mice do form less PGE 2 but higher levels of PGI 2 and thromboxane A 2 following zymosan injection (5), and LPS-stimulated macrophages from mPGES-1 Ϫ/Ϫ mice also synthesizes higher PGI 2 levels than control macrophages (19) .
In the present study, we also demonstrate that the PGE 2 synthetic system (COX-2 ¡ mPGES-1 ¡ PGE 2 ) is temporally associated with vulnerability toward COX-2 inhibition during the time course of P4-P8 in mice. Prolonged administration of a COX-2 inhibitor beyond this point of time does not further aggravate the renal-damaging effect. Regarding the reductions in diameter of glomeruli and thickness of the cortical area, COX-2 inhibition by SC-236 between P1 and P8 is equipotent to genetic COX-2 knockout. Of note, SC-236 is known to accumulate in the kidney and to exert strong COX-2 inhibition (34). Therefore, we also studied the temporal effect of rofecoxib on renal morphology. Application of rofecoxib until P8 caused renal defects not distinguishable from SC-236. This demonstrates that both growth of the glomeruli and growth of renal cortex are mainly regulated by COX-2-derived prostaglandins in mice. Interestingly, regarding the arrest of superficial glomeruli, postnatal inhibition of COX-2 is less effective in causing an increase in the relative number of superficial glomeruli compared with COX-2 Ϫ/Ϫ . We hypothesize that this finding is due to missing COX-2 activity in prenatal phases of nephrogenesis in COX-2 Ϫ/Ϫ . In support of this assumption, human and rat kidney COX-2 expression has been observed in early fetal stages of nephron development (21, 22, 45) . In mice, nephrogenesis starts at embryonic day 11.5, and the first glomeruli are formed thereafter; thus postnatal COX-2 inhibition does not compromise these early developmental and maturational steps.
Administration of SC-236 after P10 does exert only minor effects on glomerular size and superficial glomeruli, and in mice starting injection of SC-236 after P12, even no differences from control mice are visible. This shortens the time frame for vulnerability toward COX-2 inhibition to P1-P8, with the most sensitive time point around P8. However, subcapsular cortical thickness was affected by COX-2 inhibition beyond P10, a time frame when COX-2 expression is low. Although observed cortical thinning was less pronounced compared with COX-2 inhibition before P10, this finding may indicate that kidney growth, at least in part, is also modulated by low COX-2 level-derived prostaglandins. Therefore, we suggest that a continuous basal level of prostaglandins may be necessary to ensure normal cortical growth until adulthood. With respect to further kidney damages, continuous inhibition of COX-2 for 10 days is required to affect renal cell proliferation, and at least for 20 days to cause the appearance of glomerular fibrosis.
A striking observation in the present study was that mice treated with a COX inhibitor on P1 and P2, a time point when COX-2 and mPGES-1 expression are still on a basal level, already show kidney damage presented by significantly downsized glomeruli and reduced renal cortical thickness. Mean glomerular volume is nearly halved by this early COX-2 inhibition. In mice, the rate of increase in the density of nephrons per square millimeter accelerates between birth and P2 (13); therefore, a high fraction of glomerular anlagen may already be vulnerable to prostaglandin depletion at this time point. Extrapolated to a human clinical setting, one may speculate as to whether single high-dose usage of a coxib or a nonsteroidal anti-inflammatory drug during a prostaglandinsensitive time frame is able to interfere with kidney development in a similar way. Of note, low nephron mass is associated with the development of hypertension (2) and, at least in some ethnic populations, with the concurrence of cardiovascular and renal disease risks in later life (1) . Whether reduced glomerular size will cause a similar risk for hypertension as for reduced nephron number is still unknown, but likely, as both reduction in number and reduction in size will cause a decrease in glomerular filtration rate.
Although clear evidence is given that a postnatal rise in COX-2 expression and most likely also in mPGES-1 expression is a prerequisite for normal kidney development and maturation, less clear are the triggers for enzyme induction and the physiological processes actuated by PGE 2 . Evidence is given that expression of both COX-2 and mPGES-1 could completely be blocked by glucocorticoids, and it may be hypothesized that regulation of COX-2 and mPGES-1 expression in the developing kidney involves glucocorticoids. In rodents, glucocorticoid levels decrease precipitously at parturition and remain very low (14) . On the other hand, postnatal supplementation with glucocorticoids suppressed renal COX-2 in rats (27, 47) . We speculate that the drop in ambient glucocorticoid levels promotes the rise in renal COX-2 and mPGES-1 expression.
Regarding the developmental role of PGE 2 , possibly an interaction with the renin-angiotensin-aldosterone system (RAAS) does exist. In rats, COX-2 contributes to elevated renin in the early postnatal period (38) , and in the adult kidney PGE 2 is able to activate RAAS via EP2 and EP4 receptors (10, 35) . Next to EP1, both receptor types were identified by us to be involved in nephrogenesis in mice. Moreover, the RAAS is known to play a role in kidney development, and genetic or pharmacological knockout of the RAAS also causes renal developmental defects (16) . Further studies will be necessary to identify the signaling mediators involved next to prostaglandins.
